London and San Sebastián, Spain – September 12, 2026 -- EpilepsyGTx has partnered with AAV-focused CDMO Viralgen to manufacture EPY201, an investigational gene therapy targeting focal refractory epilepsy (FRE), a condition affecting an estimated 10 million patients worldwide, including 2 million across the US, UK and EU.